At the international congress of EAPC clinicians, public health care providers discussed the barriers to access to opioid medicines and the international law related with this human right.
This article aims to summarise the contents of the two reports on drug policy presented by the OAS in Colombia, as well as highlight some confusions and omissions.
IDPC has now published three reports and organised a side event at CND and a high-level seminar to promote more efficient strategies to manage illicit drug markets.
In February, IDPC held a meeting in the UK with some of its members to review its mission, vision and strategy for the coming three years, and to empower a group of individuals to speak on behalf of the Consortium at events and conferences.
As a response to rising levels of use, particularly in South East Asia, the CND has passed resolutions urging member states to employ national control systems to restrict the use of ketamine to medical and scientific purposes within their own jurisdictions, but INCB fails to account for the broader health implications of its proposal.
The meeting aimed to mend broken relationships, establish a platform for future engagement, and develop a clear action plan for the coming two years to address the concerns that had been raised.
The revised guidance provides countries with a more user-friendly framework of indicators and targets – including important new measures of the drug policy environment in which they operate.
